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The peripheral nervous system is critically involved in bone metabolism, osteogenesis, and bone remodeling. Nerve
fibers of sympathetic and sensory origin innervate synovial tissue and subchondral bone of diathrodial joints. They
modulate vascularization and matrix differentiation during endochondral ossification in embryonic limb development,
indicating a distinct role in skeletal growth and limb regeneration processes. In pathophysiological situations, the
innervation pattern of sympathetic and sensory nerve fibers is altered in adult joint tissues and bone. Various resident
cell types of the musculoskeletal system express receptors for sensory and sympathetic neurotransmitters. Osteoblasts,
osteoclasts, mesenchymal stem cells, synovial fibroblasts, and different types of chondrocytes produce distinct subtypes
of adrenoceptors, receptors for vasointestinal peptide, for substance P and calcitonin gene-related peptide. Many
of these cells even synthesize neuropeptides such as substance P and calcitonin gene-related peptide and are
positive for tyrosine-hydroxylase, the rate-limiting enzyme for biosynthesis of catecholamines. Sensory and
sympathetic neurotransmitters modulate osteo-chondrogenic differentiation of mesenchymal progenitor cells
during endochondral ossification in limb development. In adults, sensory and sympathetic neurotransmitters are
critical for bone regeneration after fracture and are involved in the pathology of inflammatory diseases as rheumatoid
arthritis which manifests mainly in joints. Possibly, they might also play a role in pathogenesis of degenerative joint
disorders, such as osteoarthritis. All together, accumulating data imply that sensory and sympathetic neurotransmitters
have crucial trophic effects which are critical for proper limb formation during embryonic skeletal growth. In adults,
they modulate bone regeneration, bone remodeling, and articular cartilage homeostasis in addition to their classic
neurological actions.Introduction
Clinical observations demonstrated the importance of the
peripheral nervous system for maintaining body homeo-
stasis and mediating organogenesis and tissue repair. It is
reported that in patients with head injuries, fractures fre-
quently heal with excessive callus formation and at a faster
rate than normal [1]. In patients with spinal cord injuries,
a profound decrease of sublesional bone mineral density
was measured in comparison with controls [2]. This loss
of bone mass is higher at the distal femur and proximal
tibia, which are the most common sites of fractures. In
addition, hip fracture after stroke is an increasingly rec-
ognized problem. Measures to prevent bone loss, whichCorrespondence: susanne.graessel@klinik.uni-regensburg.de
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months following its publication. After this t
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reproduction in any medium, provided the ois a potent risk factor for fracture, and to preserve bone
architecture have not been part of stroke management
thus far [3].
These and other recent publications suggest that the
peripheral nervous system is critically involved in bone
metabolism, osteogenic differentiation of precursor cells
(osteogenesis), bone mineralization, and bone remodel-
ing [4,5]. Nerve fibers of sympathetic and sensory origin
frequently innervate trabecular bone, periosteum, and
fracture callus [6,7]. They are involved in controlling
vascularization and matrix differentiation during endo-
chondral ossification in embryonic limb development
[8], indicating a distinct role in modulating skeletal growth
and limb formation processes.
On one hand, disorders of nerves (central or peripheral)
can have substantial influence on bone health, repair, andhe licensee has exclusive rights to distribute this article, in any medium, for 6
ime, the article is available under the terms of the Creative Commons
.org/licenses/by/4.0), which permits unrestricted use, distribution, and
riginal work is properly cited.
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density and distribution of sympathetic and sensory nerve
fibers are reported in musculoskeletal pathophysiology.
Changes in the density of sympathetic nerve fibers, which
are characterized by tyrosine-hydroxylase (TH) or neuro-
peptide Y (NPY) or both, in synovial tissue contribute to
rheumatoid arthritis (RA) [9]. Loss of sensory joint innerv-
ation during aging is suggested to accelerate degenerative
cartilage alterations which contribute to development of
spontaneous osteoarthritis (OA) in mice [10]. Capsaicin-
sensitive sensory neurons contribute to the maintenance
of tibial and femoral metaphyseal trabecular bone integrity
and bone mass [11], suggesting a positive role in bone
regeneration, whereas with respect to the sympathetic
nervous system, some studies reported a favorable influ-
ence of β-blockers on bone mass and reducing fracture
risk [12].
Sensory nerves in general contain two different noci-
ceptive neuropeptide families: the tachykinins [13] and
calcitonin gene-related peptides (CGRPs). Effects of all
tachykinins are mediated by three neurokinin receptors
with varying affinities for the individual ligands [14]
(Table 1). Classically, tachykinin substance P (SP) is known
as a mediator of nociception and of inflammation [15].
CGRP is encoded together with calcitonin and is generated
by alternative splicing [16] and signals through a complex
family of receptor proteins [17] (Table 1). The most im-
portant neurotransmitter of the catecholaminergic sym-
pathetic nervous system is norepinephrine (NE), which
signals through α- and β-adrenoceptors (ARs), depend-
ing on concentration [18] (Table 2). Vasoactive intes-
tinal peptide (VIP) belongs to a family of structurally
related peptides, including secretin, glucagon, gastric in-
hibitory peptide, growth hormone-releasing factor, and
pituitary adenylate cyclase-activating polypeptide (reviewed
in [19]). The three different subtypes of VIP receptors be-
long to the type II family of G protein-coupled receptorsTable 1 Mammalian sensory neurotransmitters and their rece
Neurotransmitters Receptor (highest affinity)
Substance P (SP) Neurokinin (NK)1 receptor
Neurokinin A (NKA) NK2 receptor
Alternatively spliced forms are
neuropeptides (NP) K and NPγ.
Neurokinin B (NKB) NK3 receptor
Hemokinin 1 (HK1) NK1 receptor, HK1 receptor?
Alternatively spliced forms are
endokinins (EK) A, B, C, D.
Alpha-calcitonin-gene-related
peptide (αCGRP)
Calcitonin receptor-like receptor (CRLR)/
receptor activity-modifying protein (RAM
Beta-calcitonin gene-related
peptide (βCGRP)
CRLR/RAMP-1(Table 2). Here, a concise overview of efferent functions
and roles of sympathetic and sensory nerve fibers and their
neurotransmitters in bone and cartilage physiology and
pathophysiology is presented.
Sensory and sympathetic nerve fibers in cartilage
physiology and development
In diarthrodial joints, permanent hyaline cartilage covers
the surface of bones and enables them to bear very large
compressive loads without distortion and allows smooth,
frictionless movement of the joints [20]. Importantly,
unlike other musculoskeletal connective tissues such as
periosteum and synovium, cartilage does not contain
blood vessels and is not deeply innervated by nerve fi-
bers, indicating that cartilage for some reason might be
a hostile environment for the spreading of nerve fibers.
However, there is sparse evidence that sensory nerve fi-
bers come into contact with those chondrocytes located
in growth plate cartilage and in the outer layer of articu-
lar cartilage. In rat knee joints, CGRP-positive fibers
which originate from periosteum and near insertion re-
gions of muscle and tendons penetrate the outer layer of
articular and meniscus cartilage up to 25 μm and are
located between single chondrocytes, indicating a local
effector function. However, there are subpopulations of
SP-positive axons in perichondrium and periosteum
which for unknown reasons do not innervate the cartil-
age [21]. CGRP- and SP-positive nerve fibers precede
the development of cartilage canals which are formed
during skeletal growth shortly after birth and were de-
tected when they penetrated the canals of growth cartil-
age in the epiphysis of young rats, thereby coming into
close contact with chondrocytes [22,23]. The develop-
ment of the secondary ossification center is subsequent
to the presence of cartilage canals carrying sensory nerve
fibers, and it is speculated that these nerve fibers modulate
the formation of synovial joints through trophic effectsptors
Neuropeptide genes Neuropeptide
receptor genes
Tachykinin (TAC) 1 or PPT-A
or PPT-I
Tachykinin receptor (TACR) 1
TAC1 TACR2
TAC3 or PPT-B or PPT-II TACR3




Table 2 Mammalian sympathetic neurotransmitters and their receptors
Neurotransmitters Receptors Neuropeptide genes Neurotransmitter receptor genes
Catecholaminergic
Norepinephrine or noradrenaline (NA) ≤10−8 M: α 1a-, b-, d- adrenoceptors ADRA1A, ADRA1B, ADRA1D
≤10−8 M: α 2a-, b-, c-adrenoceptors ADRA2A, ADRA2B, ADRA2C
≥10−6 M: β1-, β2-, β3-adrenoceptors ADRB1, ADRB2, ADRB3
Peptidergic
Vasoactive intestinal peptide (VIP) VIP-1, VIP-2, and VIP/PACAP receptors VIP VIPR1, VIPR2
PACAP, pituitary adenylate cyclase-activating polypeptide.
Grässel Arthritis Research & Therapy 2014, 6:485 Page 3 of 13
http://arthritis-research.com/content/16/6/485[24]. This observation implies important functions of sen-
sory nerves for regulating chondrogenic differentiation
during limb growth in embryonic development. In line
with this, Edoff and colleagues [22,25] reported that ar-
ticular chondrocytes respond specifically to the applica-
tion of CGRP by increasing the cAMP level. They assume
that dorsal root ganglion neurons which project to growth
plate cartilage may influence chondrocyte differentiation
via CGRP. It is described that increased levels of cAMPFigure 1 Role of sensory and sympathetic neurotransmitters and thei
(SP) and calcitonin gene-related peptide (CGRP) - and sympathetic (norepin
and propranolol) affect chondrogenic differentiation and metabolism of ch
These neurotropic effects are mediated through specific receptors for sens
(CLR) and mainly the sympathetic β2-adrenoceptor. A line with an arrow in
(green) nerve ending represent sensory (sympathetic) nerve fibers. Number
review. β2, β2-adrenoceptor; Iso, isoproterenol; Pro, propranolol.suppress terminal differentiation of chondrocytes and
matrix mineralization [26] which makes it likely that
local release of CGRP can delay chondrocyte hyper-
trophy and subsequent terminal differentiation through
modulating cAMP level (Figure 1). Whereas sympathetic
nerve fibers have been abundantly localized to subchon-
dral bone marrow [27] and synovial joint tissues [28], no
reports exist about close contact to chondrocytes or in-
nervation of healthy articular cartilage.r receptors in chondrogenic differentiation. Sensory - substance P
ephrine; NE) neurotransmitters and antagonists/agonists (isoproterenol
ondroprogenitor cells and bone marrow-derived stem cells (BMSCs).
ory neuropeptides, neurokinin 1 (NK1) receptor and CGRP receptor
dicates stimulation, and a line with a bar indicates inhibition. The red
s indicate references according to bibliography at the end of this
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osteoarthritis
OA, a degenerative disorder of diathrodial joints culmin-
ating in the irreversible destruction of the articular car-
tilage, is clinical highly relevant and a burden for the
health-care system and society because of high costs for
diagnosis, treatment, sick leave, rehabilitation, and early
retirement [29]. However, OA is not exclusively a dis-
order of articular cartilage; it can be considered an organ
failure of the whole joint with additional abnormalities
especially in subchondral bone, ligaments, synovium, and
the joint capsule. Suri and colleagues [30] have localized
both sensory (SP- and CGRP-positive) and sympathetic
(NPY-positive) nerve fibers in similar distributions to the
articular cartilage in human tibiofemoral OA. In the patho-
genesis of OA, nerves grow into joint structures through
vascular channels mainly from subchondral bone breach-
ing through the tidemark. The exclusively perivascular
localization of nerves in the articular cartilage implies that
vascularization is the driving force behind its innervation.
Notably, vascularization of the non-calcified cartilage was
found throughout a wide range of histological OA stages
and was not restricted to end-stage OA. Possibly, scoring
of nervous innervation and vascularization of cartilage
might be exploited as a measure for severity of degradative
changes in OA pathogenesis. The authors suggest that in-
nervation of the articular cartilage is therefore a potential
source of pain in patients with knee OA. These authors
and others have also shown sympathetic and perivascular
sensory innervation of tibial osteophytes, the latter local-
ized to the base of osteophytes [30,31]. Sensory innervation
of osteophytes may explain why radiological grading of
osteophytosis is associated with reported pain severity [32].
However, despite the clinical importance of pain in OA,
pain mechanisms are poorly understood. It is unclear
which structures in the joint give rise to OA pain, and
the nature of OA pain (nociceptive versus neuropathic)
is a matter of ongoing discussion [33].
In line with Suri and colleagues [30], it was recently
demonstrated that there was a marked preponderance of
sensory over sympathetic nerve fibers in ankle bone and
synovial tissue in patients with OA compared with pa-
tients with anterior knee pain after primary arthroplasty
[34]. In patients with chronic RA and end-stage OA, this
study of synovial tissues demonstrated a preponderance
of SP-positive nerve fibers relative to CGRP-positive
nerve fibers in patients with RA but not in patients with
end-stage OA. Here, an even balance exists between SP-
positive and CGRP-positive nerve fibers. Finally, the
authors observed a positive correlation between the
density of CGRP-positive and sympathetic nerve fibers
in OA, which they interpreted as an anti-inflammatory
signal. Such a positive correlation was not observed in
synovial tissue of patients with RA, which demonstratesa markedly reduced presence of sympathetic nerve fi-
bers. Thus, in the less-inflamed tissue of patients with
OA, coupling of two anti-inflammatory pathways might
dampen the inflammatory process, a situation that is
lost in the tissue of patients with RA, indicating a neu-
roendocrine uncoupling mechanism [9]. A drastic loss
of specifically sympathetic nerve fibers in synovial joint
tissues of patients with RA has previously been demon-
strated [35]; however, it appears that during OA pathogen-
esis this does not happen. Instead, inflammatory changes
in synovium of OA joints are associated with a massive
destruction of the total capillary and neuronal, sympa-
thetic and sensory nervous network which is present in
normal synovium [36]. Notably, in a murine OA model, it
was suggested that in some soft joint tissues, CGRP- and
SP-positive nerve fibers disappeared 5 weeks after induc-
tion of OA with intra-articular injection of collagenase
[37]. This quite aggressive method of OA induction leads
to profound degenerative alterations in joint tissue after a
few weeks, comparable with late-stage OA in humans.
The mechanisms which destruct the normal vascular and
neural network are not identified yet, and also it is unclear
whether nerves are destroyed as a consequence of OA or
whether pathogenesis of OA is facilitated because of nerve
disappearance. A study by Salo and colleagues [10] indi-
cated that loss of SP- and CGRP-positive joint innervation
always preceded histological changes of cartilage degener-
ation. They used a mice model which usually developed a
mild form of OA, but surgical ablation of joint innervation
caused the development of severe patellofemoral OA.
Their findings would be consistent with the hypothesis
that an age-related loss of joint innervation may contrib-
ute to the development of OA. Whether this is compar-
able to the human situation remains to be investigated,
and insight into these mechanisms will require reprodu-
cible OA animal models resembling slow proceeding
pathogenesis of human OA and enabling longitudinal
studies from early onset of the disease on to late stages.
Nerve repellent factors in cartilage
Why it is that healthy and also mostly diseased articular
cartilage is basically not innervated is still not sufficiently
clarified. Possibly, the lack of blood vessels prevents in-
nervation or vice versa. Trying to find underlying molecu-
lar mechanisms for this unique phenomenon suggests the
presence of specific axon guidance or nerve repellent
factors in cartilage. Well known sensory and sympathetic
nerve-specific axon guidance molecules or repellent factors
belong to the semaphorin family. A selective repellent of
SP- and CGRP-positive sensory nerve fibers is semaphorin
(Sema)3A, which, besides being expressed in neuronal tis-
sues, is expressed in developing cartilage and bone [38], in
intervertebral discs [39] and recently was even found in
adult articular cartilage [40]. Gomez and colleagues [38]
Grässel Arthritis Research & Therapy 2014, 6:485 Page 5 of 13
http://arthritis-research.com/content/16/6/485showed convincingly that the Sema signaling system con-
sisting of Sema3A and its receptors plexin (Plx)-A3/neuro-
pilin (NP)-1 is expressed in resting, pre-hypertrophic, and
hypertrophic chondrocytes in growth cartilage before the
onset of neurovascular invasion during endochondral ossi-
fication. They suggest that the Sema3A/Plx-A3/NP-1 path-
way would inhibit neuro-vascularization of the cartilage
anlage early in skeletal development. This block could be
removed later and locally by the downregulation of key
receptor chains, the elimination of Sema3A-producing
cells (for example, hypertrophic chondrocytes), or by
the expression of competitors of Sema3A (such as vas-
cular endothelial growth factor (VEGF)165), for instance,
by perichondral cells and hypertrophic chondrocytes.
Inhibition of Sema3A signaling would then allow blood
vessel and nerve fiber invasion of the diaphysis and thus
the onset of endochondral ossification together with the
start of local neural or vascular regulation (or both) of
bone formation. Later, during the ossification process,
Sema3A may provide a repulsive guidance, allowing the
growing nerve fibers to be directed to their targets in
bone tissue. Another group reported that gene and pro-
tein expression of Sema3A and its receptor NP-1 was
significantly elevated in chondrocytes from OA cartilage
as compared with chondrocytes from normal cartilage
and that the Sema3A expression is closely correlated
with chondrocyte cloning, which is a characteristic fea-
ture of OA cartilage [40]. The authors imply the possi-
bility that Sema3A plays a role in the pathogenesis of
chondrocyte cloning through antagonizing and inhibition
of VEGF-mediated cell migration. All together, these stud-
ies assign a novel function to Sema in chondrogenic differ-
entiation during embryonic development and cartilage
degeneration in adults in addition to their known axon
guidance role.
Sensory and sympathetic neurotransmitters and
their receptors expressed by chondrocytes
Besides their classic function in nociception, SP and
CGRP appear to have extra functions in the musculo-
skeletal system. Lately, murine costal and human articu-
lar chondrocytes have been recognized to endogenously
produce SP and its receptor NK1 [41,42]. Earlier, SP was
immunolocalized to articular cartilage of dog shoulder
joints. Expression and localization were increased in chon-
drocytes and within the extracellular matrix after low-
impact regimented exercise, indicating a role in signaling
pathways through which chondrocytes respond to mech-
anical stimulation [43]. This was indeed demonstrated by
Millward-Sadler and colleagues [44], who suggested that
SP is involved in mechanotransduction via the NK1 re-
ceptor. They found SP to be necessary for a hyperpolari-
zation response of the cell membrane, and concomitant
changes in gene expression as a response to mechanicalstimulation indicate a role of SP in the maintenance of
articular cartilage matrix integrity and function. The
same group demonstrated that normal and OA chon-
drocytes reacted differently to mechanical stimulation
in that OA chondrocytes upregulated gene expression
of the SP encoding gene, Tac1, whereas non-OA chon-
drocytes did not respond with changes in Tac1 gene
expression [45]. In addition, we recently demonstrated
that costal chondrocytes from newborn mice when stimu-
lated with SP induced proliferation and cell-matrix adher-
ence by stimulating formation of focal adhesion contacts.
These effects are mediated specifically through the NK1
receptor [41]. Our observation implies that SP might
modulate proliferation rate of growth plate chondrocytes
and consequently terminal differentiation during endo-
chondral ossification. It is thus conceivable that, in chon-
drocyte physiology and in chondrogenic differentiation
during skeletal growth, endogenous SP production acts as
a trophic, anabolic factor and does not function as a
classic neuropeptide (Figure 1 and Table 3). However, in
adults, the detection of higher levels of SP in synovial fluid
from patients with RA and OA, and increased expression
of NK1R, indicates catabolic effects of SP on articular car-
tilage [46]. In addition, transforming growth factor-beta
and basic fibroblast growth factor play an important role
as inductor or promoter for production of SP in synovial
fibroblasts. These data are supported by Im and colleagues
[47], who elegantly demonstrated that SP induces interleu-
kin 1-beta (IL-1β) release. They propose a mechanism by
which basic fibroblast growth factor, together with SP, re-
duces proteoglycan deposition and stimulates production
and release of matrix metalloprotease (MMP)-13 in hu-
man articular chondrocytes and thus accelerates catabolic
processes in cartilage. All together, these observations sug-
gest that SP has autocrine functions and can modulate
chondrocyte metabolism and cartilage homeostasis differ-
entially during skeletal growth and in pathophysiology. As
in synovial cells where SP is described as potent mediator
of inflammation by promoting secretion of prostaglandin
E2, several MMPs [48], reactive oxygen species [49], IL-1,
and tumor necrosis factor-alpha [50], SP also seems to act
in a catabolic way in chondrocytes and to promote cartil-
age degradation. To date, there are no reports listed in
Pubmed with respect to production of CGRP and its re-
ceptors in cartilage. As in bone metabolism where CGRP
is described as an anabolic factor by stimulating osteoblast
activity and thus bone formation [51,52], one might
hypothesize that CGRP has similar anabolic effects in car-
tilage physiology.
Notably, compared with trauma patients, OA patients
have lower VIP concentration in synovial fluid [53].
VIP has been shown to predominantly possess an anti-
inflammatory action (reviewed in [54]); it is very effi-
cient at ameliorating the pathology of several models of
Table 3 Sensory and sympathetic receptors and
neurotransmitters expressed in cells and tissues of
diathrodial joints
Receptors and tissue (cells) Neurotransmitters and tissue
(cells)
NK1R Substance P
Chondrocytes of articular cartilage Chondrocytes of articular cartilage
Chondrocytes of costal cartilage Chondrocytes of costal cartilage
Proliferating and hypertrophic
chondrocytes of the growth plate
Proliferating and hypertrophic
chondrocytes of the growth plate
Chondrocytes of OA cartilage Chondrocytes of OA cartilage
Chondrocytes from fracture callus Chondrocytes from fracture callus
Osteoblasts
Osteoclasts and precursors (bone
marrow-derived macrophages)
BMSCs BMSCs
Synovial fibroblasts Synovial fibroblasts
Synovial fluid








Chondrocytes of articular cartilage
(β2-AR)
Chondrocytes of the cartilage
deep zone
Chondrocytes of costal cartilage
(β2-AR)
Costal chondrocytes
Chondrocytes of growth plates
(all zones) (β2-AR)
Hypertrophic chondrocytes of the
growth plate
Chondrocytes of OA cartilage
(β2-AR)
Chondrogenic progenitor cells
from OA cartilage (β2-AR, in vitro)
Osteoblasts (β2-AR) Osteoblasts
Osteoclasts and precursors (bone
marrow-derived macrophages)
Osteoclasts
BMSCs (β2/β3-AR) Proliferating and chondrogenic/
differentiating BMSCs in vitro




Chondrocytes of OA articular
cartilage
Chondrocytes in fracture callus
Mesenchymal cells in fracture callus
Table 3 Sensory and sympathetic receptors and
neurotransmitters expressed in cells and tissues of
diathrodial joints (Continued)
α2-Adrenoceptors
Chondrocytes of articular cartilage
Chondrocytes of the growth plate
(different zones)
Chondrocytes of fracture callus
Mesenchymal cells of fracture callus
Osteoblasts




Osteoclasts (VIP-1/-2) and PACAP Synovial fluid




AR, adrenoceptor; BMSC, bone marrow-derived stem cell; CL, calcitonin
gene-related peptide; NK1R, neurokinin 1 receptor; OA, osteoarthritis; PACAP,
pituitary adenylate cyclase-activating polypeptide; RA, rheumatoid arthritis;
RAMP, receptor activity-modifying protein; VIP, vasoactive intestinal peptide.
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leagues [55] showed that treatment with VIP significantly
reduced the incidence and severity of collagen-induced
arthritis, abrogating joint swelling and the destruction of
cartilage and bone. These therapeutic effects were associ-
ated with the downregulation of both inflammatory and
autoimmune components of the disease [55]. It might be
suggested that VIP concentration in synovial fluid is nega-
tively associated with progressive joint damage in OA and
has potential as an indicator of disease severity.
Not much is known about production of sympathetic
neurotransmitters and their receptors in chondrocytes.
β2- and α2a-ARs have been found on growth plate chon-
drocytes at different developmental stages [56-58], and ex-
pression of β2- and α1/α2-ARs was detected in neonatal
murine costal chondrocytes [41] and in adult human ar-
ticular OA chondrocytes [45] (Table 3 and Figure 1). In
general, it appears that signaling through β2-ARs inter-
feres with chondrogenic differentiation by inhibiting colla-
gen II, collagen X, and Indian hedgehog expression in part
through repression of sox6 and sox9 signaling [56-58]. In
addition, we demonstrated that signaling through β2-ARs
inhibits apoptosis of murine costal chondrocytes and in-
creases cell-matrix adhesion in vitro [41]. In this line, Lai
and Mitchell [56] showed that signaling through β2-ARs
stimulates murine growth plate chondrocyte proliferation
and inhibits terminal differentiation. All together, these
sparse data on sympathetic effects in chondrocytes imply
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differentiation by suppressing production of important
chondrogenic matrix molecules (Figure 1). This note
is corroborated by recent work from Jenei-Lanzl and
colleagues [59], who clearly showed that NE stimulation of
human adult chondroprogenitor cells inhibits collagen
II and glycosaminoglycan production and accelerates
the hypertrophic pathway by induction of collagen X
and MMP-13 expression, which is opposite to the above
reports. In this study, no change in proliferative activity
of progenitor cells was observed. This might be because,
in the above studies, growth plate chondrocytes were
analyzed reflecting an embryonic chondrogenic differ-
entiation status whereas Jenei-Lanzl and colleagues [59]
investigated chondrogenic differentiation of adult mes-
enchymal stem cells and chondrogenic progenitor cells
from OA cartilage. In line with this, Li and colleagues
[60] showed that β2/3-AR gene and protein expression
is increased during adipogenic differentiation of murine
bone marrow-derived stem cells (BMSCs). Application
of β-AR antagonists positively affects adipogenic differen-
tiation, whereas agonists suppress adipogenic differenti-
ation of BMSCs by downregulating adipogenic marker
genes. The authors suggest that these effects are mediated
by increased intracellular cAMP level which activates
the PKA pathway which presumably mediates down-
regulation of two key adipogenic transcription factors:
C/EBPα and C/EBPβ.
In conclusion, one can speculate that sympathetic neu-
rotransmitters (for example, NE) alter chondrogenic dif-
ferentiation of chondrogenic progenitor cells by inhibiting
chondrocyte hypertrophy via β-ARs during embryonic
endochondral ossification (Figure 1 and Table 3). In
adults, NE might reduce the self-regeneration capacity
of articular cartilage by accelerating the hypertrophic
pathway and thus play a role in development and mani-
festation of OA. In addition, signaling through β-AR in-
hibits adipogenic differentiation of BMSCs which might
be important in the pathogenesis of obesity and osteo-
porosis in adults.
Sensory and sympathetic nerve fiber innervation
in bone tissues
Several reports have demonstrated an intensive network
of sensory and sympathetic nerve fibers within the skel-
eton, not only in the periosteum but also within tra-
becular and less in cortical bone, bone marrow, and
epiphyseal growth plate [19,23,61-63]. Many of those
nerve fibers are associated with blood vessels, but sev-
eral blood vessel-unrelated nerves and free nerve end-
ings have also been observed. Besides the possibility
that sensory and sympathetic nerve fibers have import-
ant roles in skeletal pain transmission, accumulating
evidence suggests that sensory and sympathetic nervefibers do have a role in bone remodeling and osteogenic
differentiation of precursor cells during skeletal growth.
In bone, the areas with the highest metabolic activity
receive the richest sensory and sympathetic innervation
[64]. This is in line with a study by Offley and colleagues
[11], who used selective lesioning of the unmyelinated
sensory neural pathway to determine the role of capsaicin-
sensitive sensory SP- and CGRP-containing afferents
in the maintenance of normal bone balance in skelet-
ally mature rats. Collectively, their results indicate that
capsaicin-sensitive sensory neurons contribute to ske-
letal homeostasis and that lesioning these neurons
caused enhanced bone resorption, a reduction in new
bone formation, a subsequent loss of trabecular con-
nectivity and thickness, and ultimately an increase in
bone fragility [11].
Very importantly, bone cells express receptors for
many of the neuronal messengers present in these skel-
etal nerve fibers, and activation of such receptors leads
to profound effects on the activity of both osteoblasts
and osteoclasts, strongly suggesting the existence of
neuro-osteogenic or neuro-immuno-osteogenic interac-
tions (Table 3 and Figure 2).
Experimental studies have provided accumulating evi-
dence that peripheral nerve fibers not only are important
in normal bone homeostasis and skeletal growth but also
influence repair mechanism after bone trauma (for ex-
ample, fracture healing). Aro [65] demonstrated that, in
denervated limbs, fracture callus size was clearly reduced
at a later stage of the healing process. Other studies
demonstrated larger callus formation after nerve resec-
tion [7,66] and corroborate the observation that bone
union is faster and fracture callus volume is increased in
patients with head injuries involving coma without clarify-
ing whether this is neuronal, mediated as a direct conse-
quence of the head injury or metabolical, or biochemical
as an indirect consequence [1]. At early time points after
fracture, TH-, CGRP-, and SP-positive fibers grow into the
callus prior to vascularization whereas at later time points
these nerve fibers retract to the periosteum [62,67]. Li and
colleagues [68] elegantly demonstrated in an angular rat
fracture model that innervation of CGRP-positive nerves
is higher at the concave compared with the convex site of
the fracture. The site-specific changes in CGRP innerv-
ation correlate with the amount of bone formation on
both the convex and concave sides of angular fractures.
Given that the concave side of the angular fracture re-
quires more bone formation than the convex to correct
the deformity and that CGRP was clearly more abundant
on the concave side, it is reasonable to assume that the
peripheral sensory nervous system plays an important role
in local bone turnover and that a restored nerve supply
could be essential for normal bone regeneration during
fracture healing.
Figure 2 Neurotransmitters/neuropeptides influence bone homeostasis via their receptors. Norepinephrine (NE), vasoactive intestinal
peptide (VIP), substance P (SP), and calcitonin gene-related peptide (CGRP) affect bone formation and bone resorption by modulating osteogenesis
and osteoclastogenesis in different, partly opposing ways. The effects are mediated through neurokinin 1 (NK1) receptor and CGRP receptor (CLR) and
both α- and β2-adrenoceptors, depending on catecholamine concentration. A line with an arrow at the end indicates stimulation, and a line with a
bar at the end indicates inhibition. The red (green) nerve ending represent sensory (sympathetic) nerve fibers. Numbers indicate references
according to bibliography at the end of this review. β2, β2-adrenoceptor; BMM, bone marrow-derived macrophages; M-CSF, granulocyte/
macrophage colony-stimulating factor; OPG, osteoprotegerin; RANK, receptor activator of nuclear factor kappa-B; RANKL, receptor activator of
nuclear factor kappa-B ligand; TRAP, tartrate-resistant alkaline phosphatase.
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the control of osteoclast formation because destruction of
nerves expressing VIP by guanethidine treatment in-
creases the number of osteoclasts [69]. The underlying
mechanisms hint to inhibition of osteoclast formation by
inhibiting the stimulatory effect of vitamin D3 (1,25(OH)
2D3) [70]. This inhibition of osteoclast formation through
VIP is mediated via its inhibiting effect on vitamin D3-
induced upregulation of receptor activator of nuclear
factor kappa-B (RANK) and its ligand (RANKL) and by
counteracting a decrease of osteoprotegerin (OPG) caused
by vitamin D3 (Figure 2). Thus, VIP would be an excellent
candidate that might influence inflammatory processes.
Typically, sympathetic nerve fibers carry the two markers
TH and NPY, which are important determinants of thecatecholaminergic phenotype [71]. However, this can
change because there likely exists a bidirectional com-
munication between sympathetic nerve fibers and mes-
enchymal tissue which influences the neurotransmitter
phenotype. For example, periosteal tissue can change
the neurotransmitter phenotype of sympathetic nerve fi-
bers [72]. The contact of periosteal cells with sympathetic
nerve fibers changes the catecholamine phenotype, lead-
ing to a peptidergic and cholinergic phenotype (VIP and
acetylcholine instead of NE). It is suggested that several
cytokines of the gp130 family and neurotrophic factors
determine the switch [73]. During development or under
inflammatory conditions such as in arthritis or OA, sym-
pathetic innervation of bone might change, leading to
completely different control of bone homeostasis.
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sympathetic nervous system in the mechanism of bone
loss in long-term microgravity in space [74]. The authors
suggest that an exposure to prolonged microgravity may
enhance sympathetic neural traffic not only to muscle
but also to bone. This sympathetic enhancement increases
plasma NE level, inhibits osteogenesis, and facilitates bone
resorption through β-ARs signaling which in combination
leads to reduced bone mass. They suggest that the use of
β-AR blockers to prevent bone loss in microgravity may
be reasonable, which is in line with suggestions that β-
blockers may reduce bone loss and fracture risk in post-
menopausal women [12]. On the other hand, Sherman
and Chole [75] report that low NE concentrations which
are observed after chemical sympathectomy induce
bone resorption and decrease bone formation. There-
fore, there is not an adequate evidence base to support
using β-blockers as a treatment for osteoporosis, nor
can β-blockers be regarded as a discriminating risk fac-
tor for fracture assessment. Until there are definitive
randomized controlled trials with β-blockers, which in-
clude fracture as an endpoint, it is unlikely that the
current confusing situation will be resolved [12].
Sensory innervation in bone also might play a role in
degenerative musculoskeletal disorders as in OA. In dia-
throdial joints, the subchondral bone contains sensory
nerve fibers [76]; however, subchondral regions of nor-
mal knee joints are sparsely innervated by SP- and
CGRP-nociceptive fibers [77]. SP- and CGRP-positive
nerve fibers were identified in the subchondral bone of
patients with OA, but it is still unclear whether both
sensory nerve fiber types display increased sensitivity or
number in OA joints [37]. Both types of nerve fibers
have been localized in osteophytes, and perivascular SP-
positive nerve fibers were found at the base of osteo-
phytes in horse metacarpophalangeal OA [30,31]. In
addition to SP-positive sensory nerve fibers, cells resi-
dent in cystic lesions (that is, vascular channels) of the
subchondral bone plate of OA knee joints stained posi-
tive for SP itself [78]; however, the nature of these cells
could not be identified. This note is supported by the
observation that SP protein staining in areas of remod-
eling and in erosion channels of the subchondral bone
is increased in OA pathogenesis but no respective nerve
fibers were identified [79]. How changes in sensory and
sympathetic joint innervation and their respective neu-
rotransmitters contribute to abnormal subchondral
bone remodeling and osteophyte formation during the
pathogenesis of OA is mostly unknown.
Sensory neuropeptides and catecholamines and
their receptors produced in bone
There is accumulating evidence that sensory and sympa-
thetic neurotransmitters such as SP, αCGRP, VIP, andNE have crucial trophic effects which are essential for
proper bone metabolism and bone remodeling. In the
recent literature, some comprehensive reviews comment
on expression of αCGRP, SP, and sympathetic catechol-
aminergic (NE) and peptidergic (VIP) neurotransmitters
as well as the presence of their receptors on osteocytes,
osteoblasts, osteoclasts, bone marrow-derived macro-
phages, and BMSCs and their contribution to regulation
of osteogenic differentiation, osteoclastogenesis, and con-
sequently bone resorption and bone formation in physio-
logical and pathophysiological situations [19,51,54,80-82]
(Figure 2 and Table 3).
With respect to the sympathetic nervous system, most
cited articles report about the regulation of bone remod-
eling in adults through alteration in post-synaptic β-AR
signaling [51,82]. A recent article by Ma and colleagues
[83] addressed the contribution of endogenous sympa-
thetic signaling and NE homeostasis to the control of
bone remodeling. They convincingly demonstrated that
differentiated osteoblasts, like sympathetic presynaptic
neurons, can transport and catabolize NE and thus may
contribute to NE clearance within the richly vascularized
bone marrow microenvironment. Their findings indicate
that the control of NE reuptake by the norepinephrine
transporter is an integral part of the homeostatic system
whereby bone remodeling is regulated. These data point
to the existence of multiple endogenous regulatory path-
ways modulating bone remodeling via the control of both
NE release and NE clearance. Lastly, the authors suggest
that drugs blocking norepinephrine transporter activity,
which are used for the treatment of depression and atten-
tion deficit hyperactivity disorder, may have a deleterious
effect on the skeleton.
With respect to sensory neuropeptides, αCGRP-deficient
mice suffer from osteopenia [52], and this clearly shows
that CGRP can be considered a bone anabolic factor. The
osteopenic phenotype was caused by a significant reduc-
tion of bone formation; however, osteoblast numbers
were not affected, which suggests that CGRP regulates
mainly functional activity of osteoblasts and not their
mitotic activity. In addition, in mouse bone marrow
cultures stimulated to generate osteoclasts by 1,25(OH)
2D3, CGRP dose-dependently decreased the numbers of
tartrate-resistant alkaline phosphatase-positive multinu-
cleated cells [84]. These data need to be considered to-
gether with the notion that osteoporosis is a significant
complication of stroke as frequently patients who sur-
vive an acute stroke face hip fractures. These stroke-
related complications can be attributed to reduced bone
mass due to increase in osteoclast-mediated bone re-
sorption and subsequent decreased osteoblast-mediated
bone formation (reviewed in [3]).
Notably, a recent study aimed to analyze the effect of
CGRP on adipogenic differentiation of BMSCs [85]. The
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of peroxisome proliferator activated receptor-gamma
and upregulation of CGRP in rabbit BMSCs efficiently
suppressed alcohol-induced adipogenic differentiation
while promoting osteogenic differentiation. This is an
important observation with respect to development of
alcohol-induced osteonecrosis of the femoral head and
might have implications for future treatment strategies.
Whereas CGRP is a priori characterized as a bone ana-
bolic factor [51], SP has both bone resorbing and bone
formation activities. Some studies reported opposite
effects on bone formation for SP depending on its
concentration. Whereas SP concentrations of more than
10−8 M stimulate osteoblast differentiation and bone
matrix mineralization [86,87], SP concentrations of less
than 10−8 M block osteogenic differentiation of rat
BMSCs but induce proliferation and general protein
synthesis [88]. In addition, SP stimulates proliferation of
mesenchymal precursor cells and other cells (that is,
chondrocytes in a concentration-dependent manner).
By blocking the NK1R chemically in rats for 2 weeks,
Kingery and colleagues [89] reported a significant re-
duction in tibial and femoral cancellous bone mineral
density as observed in osteoporosis. This strongly sug-
gests a role for SP in maintaining bone integrity and
regulation of bone formation and bone resorption. An-
other observation indicates that ovariectomy which
leads to reduced levels of SP at the fracture site was ac-
companied by impaired mechanical bone properties
[90]. These reports indicate a positive effect of SP on
bone formation if high concentrations of SP are avail-
able and a negative effect if SP concentration is low or if
the neuropeptide is absent (Figure 2). In line with these
data, our group observed that absence of SP reduces
pain sensitivity and mechanical stability of bone in gen-
eral and negatively impacts on bone structure in an
adult murine model of endochondral ossification [67].
The micro-architecture of cortical bone is impaired in
SP-deficient mice (Tachykinin 1 gene-deficient), and the
absence of SP reduces bone formation rate indicated by
lower bone mass and mineralization. Notably, chemical
destruction of the sympathetic nervous system with 6-
hydroxy dopamine has even more pronounced effects
on bone architecture and bone remodeling by inducing
bone resorption without affecting bone formation.
The signaling pathways through which VIP, SP, and
CGRP effects on chondro-osteogenic differentiation or
osteoclastogenesis are mediated remain largely unknown.
Like CGRP, VIP suppresses bone resorptive activities
through regulation of RANKL/OPG expression [70]. Yoo
and colleagues [91] demonstrated that a decrease in
RANKL/OPG ratio was comparable to CGRP/VIP treat-
ment of a pre-osteoblastic cell line either in combin-
ation with sheer stress application or separately. Theyconclude that mechanical stress and VIP/CGRP regulate
bone resorptive activities in a similar cellular signal
transduction pathway. VIP effects on RANKL and OPG
are mediated by an increase in cAMP, indicating that
VIP stimulates the PKA/CREB pathway in mouse
calvarial osteoblasts, bone marrow, and stromal cells
[92,93]. However, RANKL mRNA expression in mouse
calvarial osteoblasts can also be mediated by the MEK/
ERK pathway [94] and this is in line with other reports
demonstrating involvement of MEK/ERK in intracellu-
lar signaling by VIP [95]. A recent article [96] presents
strong evidence that pro-osteogenic differentiation effects
of SP are mediated via activating the Wnt/β-catenin sig-
naling pathway. The same group demonstrates that SP in-
duces proliferation of BMSCs through activation of this
pathway [97]. Also, CGRP appears to mediate its effects
on osteoblasts through the Wnt/β-catenin pathway [98].
CGRP presumably exerts its anabolic action on bone
cells by stimulating canonical Wnt signaling through
stabilization of β-catenin and by inhibiting osteoblast
apoptosis, thus favoring local bone formation.
All together, these data imply that sensory and sympa-
thetic neurotransmitters have crucial trophic effects which
are critical for proper osteogenic differentiation and bone
metabolism during embryonic skeletal growth and bone
regeneration in adults (that is, after fracture) in addition
to their classic neurological actions.
Conclusions
Sensory and sympathetic nerves and their neurotrans-
mitters are important neuronal effectors regulating bone
and cartilage physiology and playing decisive roles in mus-
culoskeletal pathophysiology. Notably, many resident cells
of the osteoarticular system contain receptors for sympa-
thetic and sensory neurotransmitters and thus can re-
spond to their stimuli. During endochondral ossification,
sensory neuropeptide SP promotes proliferation of stem
cells and growth plate chondrocytes, whereas signaling
through β-ARs inhibits chondrogenic differentiation of
osteo-chondroprogenitor cells and terminal differentiation
of chondrocytes. In bone metabolism and bone remodel-
ing, CGRP and VIP have anabolic effects, inducing osteo-
blast activity and inhibiting osteoclastogenesis, whereas SP
also has catabolic effects depending on its concentra-
tion. Effects of the sympathetic nervous system on bone
homeostasis are complex; however, it is discussed that
blocking signaling through β-ARs can prevent bone loss,
suggesting that high catecholamine concentrations shift
the balance toward bone resorption by inhibiting osteo-
blast differentiation. During pathogenesis of OA, sym-
pathetic and sensory nerve fibers grow into cartilage
from subchondral bone. In late-stage OA synovial tissue,
there are more sensory nerves compared with sympathetic
nerve fibers; however, it appears that both types of nerves
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all data, it is more and more evident that sensory and
sympathetic nerves and their neurotransmitters critically
affect bone and cartilage physiology and are crucially in-
volved in musculoskeletal disorders.Note: This article is part of the series ‘At the interface between
immunology and neurology in rheumatic diseases’, edited by
Rainer Straub. Other articles in this series can be found at
http://arthritis-research.com/series/neurology.Abbreviations
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